The nation of Zimbabwe has turned down a substantial US healthcare agreement worth $367m (272 million pounds) spanning five years because of Washington's request for confidential information.
This move came to light after a government memo dated December was leaked, which showed President Emmerson Mnangagwa deemed the arrangement was "skewed".
An official spokesman has since stated that the US was requesting health data for research and commercial purposes but was unwilling to share the resulting advantages from any future medical innovations.
"We will now turn to the challenging and unfortunate task of ending our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had furnished over $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for further talks to secure a deal acceptable to both sides so the country's vital HIV treatment initiative can proceed.
Broader Background
This rejection comes after a comparable case in neighbouring Kenya, where a high court halted a similar deal with the US after concerns were raised about the safety of citizens' medical information.
Since returning to office recently, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
The agency had managed assistance for the US government, but Trump argued its spending was "inefficient" and his administration was pursuing direct bilateral agreements to enhance transparency and accountability.
As per reports, Sixteen nations in Africa have to date signed these new agreements, constituting more than $18.3bn in committed funds.
Specifics of the Rejected Agreement
The money for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration would have delivered extraordinary advantages for Zimbabwean communities, especially the 1.2 million currently on HIV treatment via US-supported initiatives," Tremont said.
However, government spokesperson Nick Mangwana maintained the arrangement was "asymmetrical".
"Our nation was requested to provide its genetic material and health information over an extended period, with no equivalent assurance of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that provided information," he stated.
"In essence, our nation would provide the basic resources for medical research without any assurance that the resulting innovations would be accessible to our citizens if a future pandemic emerge."
Sovereignty and International Frameworks
Mangwana further said that the US's withdrawal from the global health body and its pursuit of bilateral deals were disrupting structures already set up through the international organization.
Mangwana cited its Pandemic Benefit-Sharing scheme created to deal with potential global health emergencies.
"This mechanism is intended to ensure that when a nation contributes its data, the benefits – such as medicines and cures – are shared equitably, not monopolised solely by those with the capability to develop them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We welcome further discussions with our American counterparts on how subsequent co-operation might be designed in a way that honours the sovereignty and interests of each country."
Medical Community Reaction
Medical experts said it understood the official position, but suggested that talks need to persist considering much of the country's Aids initiatives were funded by external financing.
"If specific concerns exist, such as those involving information security or implementation frameworks, these can often be addressed through detailed discussion and negotiated safeguards," the group added.
The halted deal highlights the continuing debate between accepting crucial foreign assistance and safeguarding national sovereignty in an ever more data-driven world.